Stakeholders may believe that FDA can systematize patients’ willingness to take more risk into the drug review process, but agency official Robert Temple said the way those opinions influence approvals likely will remain subjective.
Drug developers and others would like the agency to create a formal process for incorporating patient opinions into its decision-making